Cosentyx (secukinumab) Letter of Medical Necessity
Cosentyx (secukinumab) denials commonly cite step therapy, missing severity scoring, or IBD history. A successful LMN addresses each criterion explicitly.
FDA-Approved Indications
- ● plaque psoriasis
- ● psoriatic arthritis
- ● ankylosing spondylitis
- ● non-radiographic axial spondyloarthritis
- ● hidradenitis suppurativa
Why Cosentyx Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. TNF inhibitor not tried first (step therapy)
- 2. IBD history flagged as contraindication
- 3. Severity scoring missing
- 4. Loading vs maintenance dosing not specified
What to Include in a Cosentyx Letter of Medical Necessity
Include PASI/BSA for psoriasis, BASDAI for axSpA, prior TNF trial outcomes, and confirmation of no active IBD. Document loading dose schedule clinical justification when relevant.
Key clinical evidence to cite:
- ✓ ERASURE, FIXTURE, FUTURE, MEASURE trials
- ✓ Long-term extension data showing sustained PASI 90/100 response
Relevant guidelines:
- 📖 AAD-NPF 2019 Psoriasis Guidelines
- 📖 GRAPPA 2021 PsA Recommendations
- 📖 ASAS 2022 axSpA Update
Cosentyx Prior Authorization Criteria
Standard criteria across major US payers for Cosentyx. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → TNF inhibitor not tried first (step therapy)
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Cosentyx
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Cosentyx Prior Authorization FAQ
Why was my Cosentyx prior authorization denied?
The most common denial reasons for Cosentyx are: TNF inhibitor not tried first (step therapy); IBD history flagged as contraindication; Severity scoring missing; Loading vs maintenance dosing not specified.
What should a Cosentyx Letter of Medical Necessity include?
Include PASI/BSA for psoriasis, BASDAI for axSpA, prior TNF trial outcomes, and confirmation of no active IBD. Document loading dose schedule clinical justification when relevant.
Which payers cover Cosentyx?
Cosentyx is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem, Humana, though formulary tier and prior authorization criteria vary.